Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Oromucosal cannabis (Sativex) vs placebo Withdrawal due to adverse events · patients with pain management in patients with rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | RR 0.13 [0.01, 2.39] | 1 study · 58 participants | Low |
Oromucosal cannabis (Sativex) vs placebo Total adverse events · patients with pain management in patients with rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis (2012) · Cochrane | RR 1.82 [1.1, 3] | 1 study · 58 participants | Low |
Muscle relaxant vs control Pain ‐ 24hrs (Single dose) · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | no estimate extracted | 3 studies · 104 participants | Low |
Muscle relaxant vs control Pain ‐ 1‐2 weeks · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | no estimate extracted | 3 studies · 104 participants | Very low |
Muscle relaxant vs control Withdrawal due to Adverse Events · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | RR 2.84 [0.31, 26.08] | 5 studies · 180 participants | Very low |
Muscle relaxant vs control Total Number of Adverse Events ‐ only studies >24hrs duration · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | RR 4.03 [1.08, 15.1] | 2 studies · 74 participants | Very low |
Muscle relaxant vs control Total Number of Adverse Events ‐ single dose studies · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | RR 1.4 [0.58, 3.41] | 3 studies · 106 participants | Very low |
Muscle relaxant vs control CNS adverse events · patients with pain management in rheumatoid arthritis Muscle relaxants for pain management in rheumatoid arthritis (2012) · Cochrane | RR 5.96 [1.77, 20.08] | 2 studies · 74 participants | Very low |
CBT vs control Gambling symptom severity ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced gambling symptom severity, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 7 studies · 402 participants | Very low |
Integrative therapy vs control Gambling symptom severity ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced gambling symptom severity, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 2 studies · 137 participants | Very low |
Integrative therapy vs control Financial loss from gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced financial loss from gambling, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 2 studies · 137 participants | Very low |
Integrative therapy vs control Frequency of gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced financial loss from gambling, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 1 study · 52 participants | Low |
CBT vs control Financial loss from gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced financial loss from gambling, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 7 studies · 505 participants | Low |
CBT vs control Frequency of gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced severity of gambling, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 7 studies · 505 participants | Low |
CBT vs control Diagnoses of pathological gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced rates of pathological gambling, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | RR 0.13 [0.05, 0.31] | 2 studies · 81 participants | Low |
CBT vs control Depression symptoms ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced depression symptoms, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 4 studies · 276 participants | Low |
CBT vs control Anxiety symptoms ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced anxiety symptoms, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 4 studies · 276 participants | Low |
MI therapy vs control Gambling symptom severity ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced gambling symptom severity, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 2 studies · 163 participants | Very low |
MI therapy vs control Financial loss from gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced financial loss from gambling, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 3 studies · 244 participants | Very low |
MI therapy vs control Frequency of gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced financial loss from gambling, and thus positive outcomes1 · patients with pathological and problem gambling Psychological therapies for pathological and problem gambling (2012) · Cochrane | no estimate extracted | 2 studies · 145 participants | Very low |
Embryo culture with low oxygen concentration vs embryo culture with atmospheric oxygen concentration Live birth rate · Patients with live birth rate Low oxygen concentrations for embryo culture in assisted reproductive technologies (2012) · Cochrane | OR 1.39 [1.11, 1.76] | 3 studies · 1291 participants | Moderate |
Embryo culture with low oxygen concentration vs embryo culture with atmospheric oxygen concentration Ongoing pregnancy rate · Patients with ongoing pregnancy Low oxygen concentrations for embryo culture in assisted reproductive technologies (2012) · Cochrane | OR 1.4 [1.11, 1.77] | 3 studies · 1291 participants | Moderate |
Embryo culture with low oxygen concentration vs embryo culture with atmospheric oxygen concentration Clinical pregnancy rate · Patients with clinical pregnancy rate Low oxygen concentrations for embryo culture in assisted reproductive technologies (2012) · Cochrane | OR 1.35 [1.08, 1.67] | 4 studies · 1382 participants | Moderate |
Embryo culture with low oxygen concentration vs embryo culture with atmospheric oxygen concentration Multiple‐pregnancy rate · Patients with multiple pregnancy rate Low oxygen concentrations for embryo culture in assisted reproductive technologies (2012) · Cochrane | OR 1.33 [0.91, 1.95] | 4 studies · 1382 participants | Low |
Embryo culture with low oxygen concentration vs embryo culture with atmospheric oxygen concentration Miscarriage rate · patients with miscarriage rate Low oxygen concentrations for embryo culture in assisted reproductive technologies (2012) · Cochrane | OR 1.28 [0.86, 1.9] | 3 studies · 1291 participants | Low |
Embryo culture with low oxygen concentration vs embryo culture with atmospheric oxygen concentration Congenital abnormalities · patients with congenital abnormalities Low oxygen concentrations for embryo culture in assisted reproductive technologies (2012) · Cochrane | OR 0.2 [0.01, 4.09] | 1 study · 647 participants | Very low |
Intervention NR Overall survival Median · patients with indolent B cell lymphoid malignancy Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | 2 studies · 481 participants | Moderate |
Intervention NR All‐cause mortality Median · patients with indolent B cell lymphoid malignancy Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | 4 studies · 1202 participants | Moderate |
Intervention NR Smoking abstinence · s Interventions for smoking cessation in Indigenous populations (2012) · Cochrane | RR 1.43 [1.03, 1.98] | 4 studies · 1081 participants | Very low |
Intervention NR Attitudes ‐ readiness to quit · s Interventions for smoking cessation in Indigenous populations (2012) · Cochrane | RR 1.64 [0.82, 3.3] | 1 study · 92 participants | Very low |
Intervention NR Clinically apparent hepatitis A (low risk of bias trials) Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.09 [0.03, 0.3] | 3 studies · 41430 participants | High |
Intervention NR Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre < TCID50 ) all included trials Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.11 [0.05, 0.26] | 3 studies · 628420 participants | Very low |
Intervention NR Clinically apparent hepatitis A (low endemicity) low risk of bias Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.19 [0.08, 0.42] | 1 study · 1037 participants | High |
Intervention NR Clinically apparent hepatitis A (low endemicity) all included trials Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.19 [0.08, 0.42] | 1 study · 1037 participants | High |
Intervention NR Clinically apparent hepatitis A (high endemicity) low risk of bias Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.05 [0.01, 0.17] | 2 studies · 40393 participants | High |
Intervention NR Clinically apparent hepatitis A (high endemicity) all included trials Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.08 [0.04, 0.15] | 8 studies · 731343 participants | Very low |
Intervention NR Clinically apparent hepatitis A (single dose regimen) low risk of bias Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.03 [0, 0.47] | 1 study · 274 participants | High |
Intervention NR Clinically apparent hepatitis A (single dose regimen) all included studies Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.07 [0.03, 0.15] | 6 studies · 690707 participants | Very low |
Intervention NR Clinically apparent hepatitis A (multiple doses) low risk of bias Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.11 [0.03, 0.4] | 2 studies · 41156 participants | High |
Intervention NR Clinically apparent hepatitis A (multiple doses) all included trials Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.14 [0.05, 0.37] | 3 studies · 41416 participants | Moderate |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.19 [0.08, 0.42] | 1 study · 1037 participants | High |
Intervention NR Clinically apparent hepatitis A (all included trials) Dienstag 1999 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.09 [0.05, 0.17] | 9 studies · 732380 participants | Very low |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.2 [0.1, 0.37] | 3 studies · 2377 participants | Very low |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.05 [0.01, 0.17] | 2 studies · 40393 participants | High |
Intervention NR Clinicially apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.06 [0.02, 0.17] | 4 studies · 164776 participants | Very low |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinicially apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.05 [0.02, 0.13] | 1 study · 564642 participants | Low |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 0.06 [0.01, 0.41] | 1 study · 585 participants | Low |
Intervention NR All‐cause mortality low risk of bias Mortality · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | RR 1.4 [0.62, 3.16] | 1 study · 585 participants | High |